期刊
CURRENT INFECTIOUS DISEASE REPORTS
卷 16, 期 8, 页码 -出版社
SPRINGER
DOI: 10.1007/s11908-014-0416-y
关键词
Adenovirus; Solid organ transplantation; Hematopoietic stem cell transplant; Bone marrow transplant
资金
- Chimerix Inc.
- CLS Behring
- ViiV Healthcare
- GSK
- Pfizer
Infections caused by adenoviruses are associated with significant morbidity and mortality in both hematopoietic stem cell and solid organ transplant recipients. The risk seems to be highest in allogeneic hematopoietic stem cell transplant recipients as well as heart, lung and small-bowel transplant recipients. Management of these infections may be difficult and includes reduction of immunosuppression whenever possible combined sometimes with antiviral therapy (mainly cidofovir). The currently available antiviral therapy is limited by the need for intravenous administration, potentially significant renal and hematologic toxicities. New emerging therapies such as brincidofovir and transfusion of adenovirus-specific T-lymphocytes may increase the available armamentarium for these potentially life-threatening infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据